text_1: Merck wins UK okay for Keytruda in lung cancer after price cut.
text_2: Britain’s healthcare cost-effectiveness watchdog NICE has recommended use of Merck’s immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service.